D
David C. Wedge
Researcher at University of Manchester
Publications - 187
Citations - 40107
David C. Wedge is an academic researcher from University of Manchester. The author has contributed to research in topics: Cancer & Somatic evolution in cancer. The author has an hindex of 59, co-authored 156 publications receiving 31552 citations. Previous affiliations of David C. Wedge include University of Oxford & University of Cambridge.
Papers
More filters
Journal ArticleDOI
In silico modelling of directed evolution: Implications for experimental design and stepwise evolution
TL;DR: Making use of the NK fitness landscape model, the effects of mutation rate, crossover and selection pressure on the performance of directed evolution are analysed and it is found that purely evolutionary techniques fare better than do model-based approaches across all but the smoothest landscapes.
Journal ArticleDOI
Multi-site clonality analysis uncovers pervasive heterogeneity across melanoma metastases.
Roy Rabbie,Roy Rabbie,Naser Ansari-Pour,Oliver Cast,Doreen Lau,Francis Scott,Sarah J. Welsh,Christine Parkinson,Leila Khoja,Luiza Moore,Luiza Moore,Mark Tullett,Kim Wong,Ingrid Ferreira,Julia M. Martínez Gómez,Mitchell P. Levesque,Ferdia A. Gallagher,Alejandro Jiménez-Sánchez,Laura Riva,Martin L. Miller,Kieren Allinson,Peter J. Campbell,Pippa Corrie,David C. Wedge,David C. Wedge,David J. Adams +25 more
TL;DR: It is demonstrated that joint analysis of cancer cell fraction estimates across multiple metastases can uncover previously unrecognised levels of tumour heterogeneity and highlight the limitations of inferring heterogeneity from a single biopsy.
Journal ArticleDOI
Fabrication of planar organic nanotransistors using low temperature thermal nanoimprint lithography for chemical sensor applications.
Jeff Kettle,S. Whitelegg,Aimin Song,David C. Wedge,Libor Kotacka,Vladimir Kolarik,Marie-Beatrice Madec,Stephen G. Yeates,Michael L. Turner +8 more
TL;DR: Novel planar nanotransistors have been fabricated and characterized from poly(3-hexylthiophene) (P3HT) and the feasibility of using such devices as highly sensitive chemical sensors is demonstrated.
Journal ArticleDOI
Population distribution and ancestry of the cancer protective MDM2 SNP285 (rs117039649)
Stian Knappskog,Liv Beathe Gansmo,Khadizha Dibirova,Andres Metspalu,Cezary Cybulski,Paolo Peterlongo,Lauri A. Aaltonen,Lars J. Vatten,Pål Richard Romundstad,Kristian Hveem,Peter Devilee,Gareth D. Evans,Dongxin Lin,Guy Van Camp,Vangelis G. Manolopoulos,Ana Osorio,Lili Milani,Tayfun Ozcelik,Pierre Zalloua,Francis Mouzaya,E. A. Bliznetz,Elena Balanovska,Elvira Pocheshkova,Vaidutis Kučinskas,L. A. Atramentova,Pagbajabyn Nymadawa,Konstantin Titov,Maria Lavryashina,Yuldash Yusupov,Natalia Bogdanova,S. M. Koshel,Jorge Zamora,David C. Wedge,Deborah Charlesworth,Thilo Dörk,Oleg Balanovsky,Per Eystein Lønning +36 more
TL;DR: SNP285C was found to be a pan-Caucasian variant and ethnic variation regarding distribution of SNP285C needs to be taken into account when assessing the impact of MDM2 SNPs on cancer risk.
Journal ArticleDOI
Concomitant inactivation of the p53- and pRB- functional pathways predicts resistance to DNA damaging drugs in breast cancer in vivo
Stian Knappskog,Stian Knappskog,Elisabet Ognedal Berge,Elisabet Ognedal Berge,Ranjan Chrisanthar,Ranjan Chrisanthar,Stephanie Geisler,Stephanie Geisler,Vidar Staalesen,Vidar Staalesen,Beryl Leirvaag,Beryl Leirvaag,Synnøve Yndestad,Synnøve Yndestad,Elise Norheim de Faveri,Elise Norheim de Faveri,Bård Ove Karlsen,David C. Wedge,Lars A. Akslen,Lars A. Akslen,Peer K. Lilleng,Peer K. Lilleng,Erik Løkkevik,Steinar Lundgren,Bjørn Østenstad,Terje Risberg,Ingvil Mjaaland,Turid Aas,Per Eystein Lønning,Per Eystein Lønning +29 more
TL;DR: It is suggested that redundant pathway(s) may compensate for loss of p53‐pathway signaling and that these are inactivated as well in resistant tumour cells and concomitant inactivation of the p53 and pRB‐ pathways predict resistance towards anthracyclines and mitomycin in breast cancer in vivo.